ArticleAmerican journal of cancer research2023

Treatment of HER2+ breast cancer: a retrospective of disease prognosis with loss of HER2 amplification on residual disease after neoadjuvant treatment in a community hospital setting.

Dariusz Uczkowski et al.PubMed ↗Full text ↗

No numbers read from the abstract.